These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800 [TBL] [Abstract][Full Text] [Related]
3. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. Asare JM; Rabik CA; Muller B; Brown PA; Cooper S Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328 [No Abstract] [Full Text] [Related]
4. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128 [TBL] [Abstract][Full Text] [Related]
5. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions. Jeha S Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889 [TBL] [Abstract][Full Text] [Related]
6. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. DeAngelo DJ Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456 [TBL] [Abstract][Full Text] [Related]
7. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926 [TBL] [Abstract][Full Text] [Related]
8. Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China. Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Yang S; Gui L; Sun Y; Shi Y Asia Pac J Clin Oncol; 2022 Apr; 18(2):e87-e95. PubMed ID: 34161657 [TBL] [Abstract][Full Text] [Related]
9. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379 [TBL] [Abstract][Full Text] [Related]
10. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018 [TBL] [Abstract][Full Text] [Related]